A Navarro1, A Valero, M J Rosales, J Mullol. 1. UGC Intercentros Valme-Rocío Alergologia, Hospital El Tomillar, Sevilla, Spain. anp01se@saludalia.com
Abstract
BACKGROUND: Second-generation oral antihistamines (AH) and intranasal corticosteroids (ICS) are the most widely used drugs for allergic rhinitis (AR). OBJECTIVE: To obtain information on the preferences for and applications of these drugs under conditions of routine clinical practice. METHODS: We performed a multicenter multidisciplinary observational study. Participating physicians completed a questionnaire with information on preferences for and application of drugs for AR, patient characteristics, and physician/patient satisfaction with the treatment provided (visual analog scale). RESULTS: A total of 1008 physicians participated in the study (primary care physicians, 53%; ear, nose, and throat specialists, 28%; allergologists, 19%). Treatment preferences in AR were AH combined with ICS (7.68), AH (7.25), and ICS (6.94). AH and ICS were used continuously by 58% and 71% of patients, respectively. Physicians reported having a good knowledge of the Allergic Rhinitis and its Impact on Asthma guidelines (93%), and 90% claimed to follow the guidelines. A total of 4040 patients were recruited (52% females, mean [SD] age 34 [14] years). The findings for AR were as follows: mean (SD) duration, 9 (8) years; persistent AR, 52%; mild AR, 72%; moderate AR, 7%; and severe AR, 1%. Patients considered the disorder to be well controlled/almost controlled (79%). As for treatment, 77% followed the regimen recommended by the physician. Oral treatment (41%) and intranasal treatment (22%) were preferred, while 35% showed no preference for any given administration route. The treatments prescribed were AH combined with ICS (66%), AH (20%), ICS (11%), other antihistamines (4%), and other drugs (6%). Combination treatment was the preferred therapy, regardless of the type of rhinitis. CONCLUSIONS: Physicians prefer and more often use combination treatment with oral AH and ICS, regardless of the frequency and intensity of AR.
BACKGROUND: Second-generation oral antihistamines (AH) and intranasal corticosteroids (ICS) are the most widely used drugs for allergic rhinitis (AR). OBJECTIVE: To obtain information on the preferences for and applications of these drugs under conditions of routine clinical practice. METHODS: We performed a multicenter multidisciplinary observational study. Participating physicians completed a questionnaire with information on preferences for and application of drugs for AR, patient characteristics, and physician/patient satisfaction with the treatment provided (visual analog scale). RESULTS: A total of 1008 physicians participated in the study (primary care physicians, 53%; ear, nose, and throat specialists, 28%; allergologists, 19%). Treatment preferences in AR were AH combined with ICS (7.68), AH (7.25), and ICS (6.94). AH and ICS were used continuously by 58% and 71% of patients, respectively. Physicians reported having a good knowledge of the Allergic Rhinitis and its Impact on Asthma guidelines (93%), and 90% claimed to follow the guidelines. A total of 4040 patients were recruited (52% females, mean [SD] age 34 [14] years). The findings for AR were as follows: mean (SD) duration, 9 (8) years; persistent AR, 52%; mild AR, 72%; moderate AR, 7%; and severe AR, 1%. Patients considered the disorder to be well controlled/almost controlled (79%). As for treatment, 77% followed the regimen recommended by the physician. Oral treatment (41%) and intranasal treatment (22%) were preferred, while 35% showed no preference for any given administration route. The treatments prescribed were AH combined with ICS (66%), AH (20%), ICS (11%), other antihistamines (4%), and other drugs (6%). Combination treatment was the preferred therapy, regardless of the type of rhinitis. CONCLUSIONS: Physicians prefer and more often use combination treatment with oral AH and ICS, regardless of the frequency and intensity of AR.
Authors: Carlos Daniel Zappia; Gina Granja-Galeano; Natalia Fernández; Carina Shayo; Carlos Davio; Carlos P Fitzsimons; Federico Monczor Journal: Sci Rep Date: 2015-12-04 Impact factor: 4.379
Authors: David B Price; Glenis Scadding; Claus Bachert; Hesham Saleh; Shuaib Nasser; Victoria Carter; Julie von Ziegenweidt; Alice M S Durieux; Dermot Ryan Journal: NPJ Prim Care Respir Med Date: 2016-06-23 Impact factor: 2.871
Authors: David B Price; Pete K Smith; Richard John Harvey; A Simon Carney; Vicky Kritikos; Sinthia Z Bosnic-Anticevich; Louise Christian; Derek Skinner; Victoria Carter; Alice Ms Durieux Journal: Pragmat Obs Res Date: 2018-08-15